PUBLISHER: Grand View Research | PRODUCT CODE: 1529851
PUBLISHER: Grand View Research | PRODUCT CODE: 1529851
The global transcatheter aortic valve replacement market size is expected to reach USD 10.2 billion by 2030, expanding at a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising geriatric population and the prevalence of risk factors like aortic valve stenosis (AS) and other diseases continue to drive the demand for transcatheter aortic valve replacement (TAVR) procedures. According to the World Heart Federation 2022, rheumatic heart disease affected 39 million individuals globally. It is a disorder in which rheumatic fever permanently damages the heart valves. According to a January 2022 published study titled "Uncovering the treatable burden of severe AS in the U.K.", the prevalence of severe AS in the U.K. in 2019 was 1.48%, affecting 291,448 men and women aged 55 or above.
As a result of these figures, the demand for TAVR is expected to rise in the coming years, contributing to the market's expansion. Furthermore, the rising prevalence of heart valve disease and increased regulatory approvals for novel and sophisticated TAVR devices drive market growth. The rising prevalence of AS disease is a main factor driving the market's expansion. For instance, in January 2022, JenaValve Technology, Inc. formed a strategic alliance with an exclusive technology licensing agreement with Peijia Medical Limited in China. According to the terms of the deal, Peijia has been granted exclusive rights in China to produce and distribute JenaValve's Trilogy TAVR systems for treating patients with significant symptomatic aortic regurgitation (AR) and severe symptomatic AS.